scholarly journals Hepatic Metastasis from Breast Cancer

2020 ◽  
Vol 37 (05) ◽  
pp. 518-526
Author(s):  
Ariel N. Liberchuk ◽  
Amy R. Deipolyi
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Locoregional Treatment ◽  
Preserve Liver Function ◽  
Potential Benefits ◽  
Hospital Stays ◽  
Poor Outcomes ◽  
Breast Cancer Liver Metastasis ◽  
Outpatient Settings

AbstractBreast cancer is the most common cancer in women and breast cancer liver metastasis may be associated with poor outcomes. Emerging locoregional therapies can be given in outpatient settings or with short hospital stays, to provide local control, support quality of life, preserve liver function, and potentially prolong survival. This review discusses retrospective studies suggesting potential benefits of locoregional treatment of breast cancer liver metastasis. Future prospective studies are needed to demonstrate efficacy and optimize patient selection.

BRECLIM - a randomized clinical trial investigating local treatment for breast cancer liver metastasis

2020 ◽  
Vol 46 (2) ◽  
pp. e14
Author(s):  
Oskar Hemmingsson ◽  
Malin Sund ◽  
Helena Taflin ◽  
Marcus Sundén ◽  
Anne Andersson
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Liver Metastasis ◽  
Randomized Clinical Trial ◽  
Local Treatment ◽  
Breast Cancer Liver Metastasis

scholarly journals Electrochemotherapy in Breast Cancer - Discussion of the Method and Literature Review

Breast Care ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. 409-414 ◽  
Author(s):  
Mateusz Wichtowski ◽  
Dawid Murawa ◽  
Katarzyna Kulcenty ◽  
Karolina Zaleska
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Locoregional Treatment ◽  
Electric Pulses ◽  
Non Invasive ◽  
Life Threatening ◽  
Late Stages ◽  
Methods Of Treatment ◽  
Cause Of Pain

Breast cancer is the most common cause of skin metastases in women. The probability of their occurrence ranges from about 5% in the entire population to as much as 30% in the late stages of the disease. Although rarely life-threatening, they have a major impact on the quality of life of patients with this diagnosis, being the cause of pain, effusion, ulceration, infection, and psychological discomfort. Available methods of treatment, both local and systemic, often fail to provide adequate control of the disease. A particular challenge seems to be the treatment of those patients with cutaneous metastases who, due to the extent of their metastases, are not eligible for resection, in whom the possibility of radiation therapy has already been used, and in whom systemic therapy is ineffective or contraindicated. A new method providing the opportunity for effective treatment is electrochemotherapy (ECT). ECT combines electropulsation of tumor cells (by local application of electric pulses) and administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). Several clinical studies have demonstrated that ECT provides safe, efficient, and non-invasive locoregional treatment for chest wall breast cancer recurrence.

scholarly journals Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 753 ◽  
Author(s):  
Wang ◽  
Li ◽  
Liu ◽  
Kinnebrew ◽  
Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Calcium Signaling ◽  
Microarray Data ◽  
Primary Breast Cancer ◽  
Cytokine Receptor ◽  
Receptor Interaction ◽  
Tgf Beta ◽  
Breast Cancer Liver Metastasis ◽  
Alternatively Activated

Alternatively-activated pathways have been observed in biological experiments in cancer studies, but the concept had not been fully explored in computational cancer system biology. Therefore, an alternatively-activated pathway identification method was proposed and applied to primary breast cancer and breast cancer liver metastasis research using microarray data. Interestingly, the results show that cytokine-cytokine receptor interaction and calcium signaling were significantly enriched under both conditions. TGF beta signaling was found to be the hub in network topology analysis. In total, three types of alternatively-activated pathways were recognized. In the cytokine-cytokine receptor interaction pathway, four active alteration patterns in gene pairs were noticed. Thirteen cytokine-cytokine receptor pairs with inverse activity changes of both genes were verified by the literature. The second type was that some sub-pathways were active under only one condition. For the third type, nodes were significantly active in both conditions, but with different active genes. In the calcium signaling and TGF beta signaling pathways, node E2F5 and E2F4 were significantly active in primary breast cancer and metastasis, respectively. Overall, our study demonstrated the first time using microarray data to identify alternatively-activated pathways in breast cancer liver metastasis. The results showed that the proposed method was valid and effective, which could be helpful for future research for understanding the mechanism of breast cancer metastasis.

scholarly journals Microwave ablation for breast cancer liver metastasis

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S943
Author(s):  
E. Gringeri ◽  
R. Boetto ◽  
S.E. Pierobon ◽  
F.E. D'Amico ◽  
D. Bassi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Microwave Ablation ◽  
Breast Cancer Liver Metastasis

scholarly journals Results of hepatic resection following breast cancer liver metastasis

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S639
Author(s):  
K. Kobryń ◽  
E. Kobryń ◽  
K. Kobryń ◽  
M. Nowosad ◽  
W. Patkowski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Hepatic Resection ◽  
Breast Cancer Liver Metastasis

Liver Transplant in Patient with Breast Cancer Liver Metastasis and Hepatic Failure

2021 ◽  
Vol 53 ◽  
pp. S46
Author(s):  
V. Giannelli ◽  
R. Meniconi ◽  
N. Guglielmo ◽  
M. Colasanti ◽  
C. D'Ambrosio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Liver Transplant ◽  
Hepatic Failure ◽  
Breast Cancer Liver Metastasis

scholarly journals Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis

2016 ◽  
Vol 264 (1) ◽  
pp. 147-154 ◽  
Author(s):  
Eran Sadot ◽  
Ser Yee Lee ◽  
Constantinos T. Sofocleous ◽  
Stephen B. Solomon ◽  
Mithat Gönen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Hepatic Resection ◽  
Breast Cancer Liver Metastasis

scholarly journals Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Kevin Rivera ◽  
Dhiresh Rohan Jeyarajah ◽  
Kimberly Washington
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Liver Metastasis ◽  
Hepatic Resection ◽  
Cancer Metastasis ◽  
Cochrane Review ◽  
Hepatic Arterial Infusion ◽  
Breast Cancer Metastasis ◽  
Arterial Infusion ◽  
Breast Cancer Liver Metastasis

BackgroundThe liver is the second most common site of breast cancer metastasis. Liver directed therapies including hepatic resection, radiofrequency ablation (RFA), transarterial chemo- and radioembolization (TACE/TARE), and hepatic arterial infusion (HAI) have been scarcely researched for breast cancer liver metastasis (BCLM). The purpose of this review is to present the known body of literature on these therapies for BCLM.MethodsA systematic review was performed with pre-specified search terms using PubMed, MEDLINE, EMBASE, and Cochrane Review resulting in 9,957 results. After review of abstracts and application of exclusion criteria, 51 studies were included in this review.ResultsHepatic resection afforded the longest median overall survival (mOS) and 5-year survival (45 mo, 41%) across 23 studies. RFA was presented in six studies with pooled mOS and 5-year survival of 38 mo and 11–33%. Disease burden and tumor size was lower amongst hepatic resection and RFA patients. TACE was presented in eight studies with pooled mOS and 1-year survival of 19.6 mo and 32–88.8%. TARE was presented in 10 studies with pooled mOS and 1-year survival of 11.5 mo and 34.5–86%. TACE and TARE populations were selected for chemo-resistant, unresectable disease. Hepatic arterial infusion was presented in five studies with pooled mOS of 11.3 months.ConclusionAlthough further studies are necessary to delineate appropriate usage of liver directed therapies in BCLM, small studies suggest hepatic resection and RFA, in well selected patients, can result in prolonged survival. Longitudinal studies with larger cohorts are warranted to further investigate the effectiveness of each modality.

Sign in / Sign up

Export Citation Format

Share Document